1
|
Gao B, Chen K, Bi X, Wang J. Intramolecular functionalization of C(sp 3 ) H bonds adjacent to an amide nitrogen atom: Metal-free synthesis of 2-hydroxy-benzoxazinone derivatives. Tetrahedron 2017. [DOI: 10.1016/j.tet.2017.09.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
2
|
Wang R, Bao W. Iron(III) acetylacetonate catalyzed tandem oxidative addition/cyclization of simple amides with alkenes: a convenient process to synthesize 3-amido oxindoles. Tetrahedron 2015. [DOI: 10.1016/j.tet.2015.07.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Yan H, Lu L, Rong G, Liu D, Zheng Y, Chen J, Mao J. Functionalization of Amides via Copper-Catalyzed Oxyalkylation of Vinylarenes and Decarboxylative Alkenylation of sp3 C–H. J Org Chem 2014; 79:7103-11. [DOI: 10.1021/jo501274f] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Hong Yan
- Key Laboratory of Organic
Synthesis of Jiangsu Province College of Chemistry, Chemical Engineering
and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
| | - Linhua Lu
- Key Laboratory of Organic
Synthesis of Jiangsu Province College of Chemistry, Chemical Engineering
and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
| | - Guangwei Rong
- Key Laboratory of Organic
Synthesis of Jiangsu Province College of Chemistry, Chemical Engineering
and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
| | - Defu Liu
- Key Laboratory of Organic
Synthesis of Jiangsu Province College of Chemistry, Chemical Engineering
and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
| | - Yang Zheng
- Key Laboratory of Organic
Synthesis of Jiangsu Province College of Chemistry, Chemical Engineering
and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
| | - Jie Chen
- Key Laboratory of Organic
Synthesis of Jiangsu Province College of Chemistry, Chemical Engineering
and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
| | - Jincheng Mao
- Key Laboratory of Organic
Synthesis of Jiangsu Province College of Chemistry, Chemical Engineering
and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China
| |
Collapse
|
4
|
Karmouty-Quintana H, Cannet C, Sugar R, Fozard JR, Page CP, Beckmann N. Capsaicin-induced mucus secretion in rat airways assessed in vivo and non-invasively by magnetic resonance imaging. Br J Pharmacol 2007; 150:1022-30. [PMID: 17351665 PMCID: PMC2013907 DOI: 10.1038/sj.bjp.0707168] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND AND PURPOSE An up-regulation of the sensory neural pathways in the lung has been implicated in asthma and chronic obstructive pulmonary disease (COPD) and is thought to contribute to mucus hypersecretion, an essential feature of both diseases. The aim of this study was to assess non-invasively the acute effects (up to 60 min) of sensory nerve stimulation by capsaicin in the lung, using magnetic resonance imaging (MRI). EXPERIMENTAL APPROACH Male Brown Norway rats were imaged prior to and 10, 30 and 60 min after intra-tracheal challenge with capsaicin (30 microg kg(-1)) or vehicle (0.5% ethanol solution). In subsequent studies, pre-treatment with the transient receptor potential vanilloid (TRPV)-1 antagonist, capsazepine; the dual neurokinin (NK) 1 and NK2 receptor antagonist, DNK333 and the mast cell stabilizer, di-sodium cromoglycate (DSCG) was used to modulate the effects of capsaicin. KEY RESULTS Diffuse fluid signals were detected by MRI in the lung as early as 10 min after capsaicin, remaining constant 30 and 60 min after treatment. Broncho-alveolar lavage (BAL) fluid analysis performed 60 min after capsaicin revealed increased mucin concentration. Capsazepine (3.5 mg kg(-1)), DNK333 (10 mg kg(-1)) but not DSCG (10 mg kg(-1)) administered prophylactically were able to block the effect of capsaicin in the airways. CONCLUSIONS AND IMPLICATIONS These observations suggest that the fluid signals detected by MRI after capsaicin administration reflected predominantly the release of mucus following activation of sensory nerves. They point to the opportunity of non-invasively assessing with MRI the influence of neuronal mechanisms in animal models of asthma and COPD.
Collapse
Affiliation(s)
- H Karmouty-Quintana
- Discovery Technologies, Novartis Institutes for BioMedical Research Basel, Switzerland
- Sackler Institute of Pulmonary Pharmacology, School of Biomedical and Health Sciences, King's College London, UK
| | - C Cannet
- Discovery Technologies, Novartis Institutes for BioMedical Research Basel, Switzerland
| | - R Sugar
- Novartis Horsham Research Centre Horsham, UK
| | - J R Fozard
- Respiratory Diseases Area, Novartis Institutes for BioMedical Research Basel, Switzerland
| | - C P Page
- Sackler Institute of Pulmonary Pharmacology, School of Biomedical and Health Sciences, King's College London, UK
| | - N Beckmann
- Discovery Technologies, Novartis Institutes for BioMedical Research Basel, Switzerland
- Author for correspondence:
| |
Collapse
|
5
|
Swarna VM, Undem BJ, Korlipara VL. Design and synthesis of 3,5-disubstituted benzamide analogues of DNK333 as dual NK1/NK2 receptor probes. Bioorg Med Chem Lett 2006; 17:890-4. [PMID: 17169559 DOI: 10.1016/j.bmcl.2006.11.064] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2006] [Revised: 11/16/2006] [Accepted: 11/20/2006] [Indexed: 10/23/2022]
Abstract
N-[(R,R)-(E)-(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide (DNK333, 1b) has been reported to be a potent and balanced dual neurokinin (tachykinin) receptor antagonist. A recent clinical trial using DNK333 has shown that it blocks the NKA-induced bronchoconstriction in patients with asthma. A series of six analogues 3-8 derived from modification of 3,5-bis(trifluoromethyl)benzamide moiety of DNK333 has been synthesized to serve as the dual NK(1)/NK(2) receptor probes. The 3,5-dinitro substituted benzamide compound 3 was found to possess potent and balanced dual NK(1)/NK(2) receptor antagonist activities (pK(b)=8.4 for the NK(1) receptors, pK(b)=7.87 for the NK(2) receptors) in the functional assay using guinea pig trachea. Furthermore, SAR analysis suggests that steric, electronic, and lipophilic characteristics of substituents in the benzamide region of DNK333 have a crucial effect on both the NK(1) and NK(2) receptor antagonist activities.
Collapse
Affiliation(s)
- Venkat Manoj Swarna
- Department of Pharmaceutical Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA
| | | | | |
Collapse
|
6
|
Yan H, Kerns JK, Jin Q, Zhu C, Barnette MS, Callahan JF, Hay DWP, Jolivette LJ, Luttmann MA, Sarau HM, Ward KW, Widdowson KL, Wan Z. A Highly Convergent Synthesis of 2‐Phenyl Quinoline as Dual Antagonists for NK2 and NK3 Receptors. SYNTHETIC COMMUN 2006. [DOI: 10.1080/00397910500281234] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Hongxing Yan
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Jeffrey K. Kerns
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Qi Jin
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Chongjie Zhu
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Mary S. Barnette
- b Department of COPD Biology , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - James F. Callahan
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Douglas W. P. Hay
- b Department of COPD Biology , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Larry J. Jolivette
- c Department of DMPK , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Mark A. Luttmann
- b Department of COPD Biology , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Henry M. Sarau
- b Department of COPD Biology , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Keith W. Ward
- c Department of DMPK , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Katherine L. Widdowson
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Zehong Wan
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| |
Collapse
|
8
|
Ohmori K, Adachi K, Manabe H, Harada D, Ohshima E. [Recent development of new drugs for the treatment of allergic diseases]. Nihon Yakurigaku Zasshi 2004; 123:335-48. [PMID: 15118258 DOI: 10.1254/fpj.123.335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Due to the prevalence of allergic diseases such as bronchial asthma, allergic rhinoconjunctivitis and dermallergosis, efforts at the discovery of novel and effective medications for prevention and treatment of these conditions have been reinforced. Recently, it has been recognized that these allergic diseases are a chronic inflammatory disorder of the lower and upper airways and skin. In this article, we reviewed the recent development of the following new antiallergic therapies: anti-Th2 cytokine antibodies, decoy receptors, receptor antibodies, anti-IgE antibodies, anti-cell adhesion molecules antibodies, antisense oligonucleotides, keratinocyte modulators, inhibitors of phosphodiesterase 4, tachykinin receptor antagonists, and anti-histaminic drugs. Most of these new agents are aimed to inhibit various components of allergic inflammation. The future use of allergic disease therapies hold great promise and excitement.
Collapse
Affiliation(s)
- Kenji Ohmori
- Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Suntogun, Shizuoka, Japan.
| | | | | | | | | |
Collapse
|